Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia

Obszański, Piotr; Anna, Kozłowska,; Wańcowiat, Jakub; Twardowska, Julia; Lejman, Monika; Zawitkowska, Joanna

doi:10.3390/molecules27123911

Cited by 12 publications

(9 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rhabdomyosarcoma is the most frequent sarcoma in children, but neuroblastoma, ES, and osteosarcoma are also common [7]. In haematological malignancies the use of venetoclax is already ongoing in clinical trials for relapsed, refractory or high-risk leukaemia [87,88]. Based on the previous findings in ES, a study in 2020 by Kehr et al [89] demonstrated that rhabdomyosarcoma, osteosarcoma, and neuroblastoma cell lines were co-dependent of Bcl-xL and MCL-1 for survival.…”

Section: Pediatric Sarcomasmentioning

confidence: 99%

B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease

Oliveira,

Gama,

Casanova

2023

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Targeting the B-cell lymphoma 2 (Bcl-2) family proteins has been the backbone for hematological malignancies with overall survival improvements. The Bcl-2 family is a major player in apoptosis regulation and, has captured the researcher’s interest in the treatment of solid tumors. Sarcomas are a heterogeneous group of diseases, comprising several entities, with high morbidity and mortality and with few specific therapies available. The treatment for sarcomas is based on platinum regimens, with variable results and poor outcomes, especially in advanced lesions. The high number of different sarcoma entities makes treatment standardization as well as the performance of clinical trials difficult. The use of Bcl-2 family members modifiers has revealed promising results in in vitro and in vivo models and may be a valid option, especially when used in combination with chemotherapy. In this article, a revision of these results and possibilities for the use of Bcl-2 family members inhibitors in sarcomas was performed.

show abstract

Section: Pediatric Sarcomasmentioning

confidence: 99%

B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease

Oliveira,

Gama,

Casanova

2023

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

show abstract

“…With current therapeutic regimens, over 50% of AML patients will relapse within 1 year, and 80% of AML patients will relapse within 5 years. [ 2 ] Therefore, research is necessary to better understand the molecular mechanisms of the initiation and progression of AML and to develop novel therapeutic approaches for AML patients, particularly for relapsed patients with a much poorer prognosis. In addition, potent drugs for the specific treatment of age-related leukemia remain undeveloped.…”

Section: Introductionmentioning

confidence: 99%

Internal m6A and m7G RNA modifications in hematopoietic system and acute myeloid leukemia

Zhang,

Ma,

et al. 2024

Chinese Medical Journal

View full text Add to dashboard Cite

Epitranscriptomics focuses on RNA modifications-mediated post-transcriptional regulation of gene expression. The current decade has witnessed tremendous progress in understanding the landscapes and biological functions of RNA modifications as prompted by potent analytical approaches. The hematopoietic system provides a lifelong supply of blood cells, and gene expression is tightly modulated during the differentiation of hematopoietic stem cells (HSCs). Dysregulation of gene expression during hematopoiesis may lead to severe disorders, including acute myeloid leukemia (AML). Emerging evidence has indicated the involvement of mRNA modification system in normal hematopoiesis and AML pathogenesis, which led to the accelerating development of small-molecule inhibitors targeting N6-methyladenosine (m6A) modification machinery for treatment. Here, we summarize the latest findings and address the state-of-the-art knowledge on the role of m6A and N7-methylguanine (m7G) in both physiological and pathological conditions in the hematopoietic system. Furthermore, we discuss the therapeutic potential and limitations of cancer treatment targeting m6A.

show abstract

“…AML often presents with fever, anemia, hemorrhage, lymphadenopathy, and hepatosplenomegaly. [1] In the past 20 to 30 years, the survival rate of childhood AML has improved significantly, with an overall survival rate of 60% to 70%, and an event-free survival rate of over 50%. [2][3][4][5][6][7] Due to the prothrombotic nature of cancer and its associated coagulopathies as well as the use of chemotherapeutic agents, the use of central venous catheters, surgery, and radiotherapy, children with cancer tend to have increased risks of thromboembolism (TE).…”

Section: Introductionmentioning

confidence: 99%

Right femoral vein and right dorsal artery thrombosis in childhood acute myeloid leukemia: A case report

Ni,

Chen,

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: It is rare for newly diagnosed (de novo) or newly treated acute myeloid leukemia (AML) complicated with thrombotic complications, especially combined arterial and venous thrombosis. Methods: We reported a 13-year-old boy diagnosed with AML and leukocytosis, who developed right femoral vein and right dorsal artery thrombosis during chemotherapy. After treatment with low molecular weight heparin, diosmin, and alprostadil, symptoms were relieved. Unfortunately, the child suffered from coagulopathy afterward, which was unexpectedly caused by vitamin K deficiency. Results: After supplementation with vitamin K and prothrombin complex concentrate, coagulation function recovered. Conclusion: For childhood AML patients with high thrombotic risks, close monitoring during anticoagulant treatment was necessary. Concomitantly, we should be alert to past medication history and combined medication use, especially those that may lead to vitamin K deficiency, secondary bleeding, and coagulation disorders. Rational use of antibiotics, anticoagulants, and antitumor drugs must be guaranteed.

show abstract

Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia

Cited by 12 publications

References 76 publications

B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease

B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease

Internal m6A and m7G RNA modifications in hematopoietic system and acute myeloid leukemia

Right femoral vein and right dorsal artery thrombosis in childhood acute myeloid leukemia: A case report

Contact Info

Product

Resources

About